High-risk human papillomavirus-associated vulvar neoplasia among women living with human immunodeficiency virus in Zambia.
HIV
Zambia
human papillomavirus virus
vulvar cancer
vulvar neoplasia
Journal
African journal of laboratory medicine
ISSN: 2225-2002
Titre abrégé: Afr J Lab Med
Pays: South Africa
ID NLM: 101603205
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
02
2021
accepted:
24
02
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Globally, women living with HIV have a higher risk of vulvar neoplasia than HIV-negative women. Vulvar neoplasia among women living with HIV has not previously been characterised in Zambia. This study determined the clinical and pathologic features of vulvar neoplasia among women living with HIV at the University Teaching Hospital, Lusaka, Zambia. We conducted a cross-sectional study of vulvar lesions among 53 women living with HIV who presented with vulvar lesions between July 2017 and February 2018. The study assessed clinical and histological characteristics and prevalence of high-risk human papillomavirus (HRHPV). Twenty-one patients were diagnosed with vulvar squamous cell carcinoma (VSCC), 20 with usual vulvar intraepithelial neoplasm (uVIN), and the rest with either benign lesions or non-neoplastic lesions (NNL). Participants' mean age was 40 years. Patients with VSCC were significantly older than those with NNL (mean (s.d.): 43 (21) vs 33 (10), VSCC was significantly more common among women aged ≥ 40 years. HRHPV in VSCC and high-grade squamous intraepithelial lesions was high. Women with vulvar lesions, especially those aged > 40 years, should be evaluated for vulvar cancer. Young girls should be vaccinated to prevent vulvar cancer.
Sections du résumé
Background
UNASSIGNED
Globally, women living with HIV have a higher risk of vulvar neoplasia than HIV-negative women. Vulvar neoplasia among women living with HIV has not previously been characterised in Zambia.
Objective
UNASSIGNED
This study determined the clinical and pathologic features of vulvar neoplasia among women living with HIV at the University Teaching Hospital, Lusaka, Zambia.
Methods
UNASSIGNED
We conducted a cross-sectional study of vulvar lesions among 53 women living with HIV who presented with vulvar lesions between July 2017 and February 2018. The study assessed clinical and histological characteristics and prevalence of high-risk human papillomavirus (HRHPV).
Results
UNASSIGNED
Twenty-one patients were diagnosed with vulvar squamous cell carcinoma (VSCC), 20 with usual vulvar intraepithelial neoplasm (uVIN), and the rest with either benign lesions or non-neoplastic lesions (NNL). Participants' mean age was 40 years. Patients with VSCC were significantly older than those with NNL (mean (s.d.): 43 (21) vs 33 (10),
Conclusion
UNASSIGNED
VSCC was significantly more common among women aged ≥ 40 years. HRHPV in VSCC and high-grade squamous intraepithelial lesions was high. Women with vulvar lesions, especially those aged > 40 years, should be evaluated for vulvar cancer. Young girls should be vaccinated to prevent vulvar cancer.
Identifiants
pubmed: 35747556
doi: 10.4102/ajlm.v11i1.1563
pii: AJLM-11-1563
pmc: PMC9210187
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1563Subventions
Organisme : FIC NIH HHS
ID : D43 TW010354
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA221204
Pays : United States
Informations de copyright
© 2022. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
Biomed Res Int. 2014;2014:480573
pubmed: 24719870
Oncol Res Treat. 2018;41(9):520-524
pubmed: 30041246
IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636
pubmed: 18354839
BMC Infect Dis. 2020 Apr 22;20(1):297
pubmed: 32321435
Pediatrics. 2011 Dec;128 Suppl 5:S213-56
pubmed: 22084329
Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 1):487-93
pubmed: 15010559
Tumori. 2017 Nov 23;103(6):511-515
pubmed: 28574130
Surg Pathol Clin. 2011 Mar;4(1):87-111
pubmed: 26837289
Cancer Res. 2001 Mar 1;61(5):1934-40
pubmed: 11280749
BMC Infect Dis. 2012 Oct 05;12:243
pubmed: 23040203
S Afr Med J. 2017 Oct 31;107(11):1000-1004
pubmed: 29262943
Pathology. 2016 Jun;48(4):291-302
pubmed: 27113549
BMJ. 2019 Apr 3;365:l1161
pubmed: 30944092
J Infect Dis. 2001 Sep 15;184(6):682-90
pubmed: 11517428
Int J Cancer. 2017 Dec 15;141(12):2517-2527
pubmed: 28815579
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
Histopathology. 2013 Jan;62(1):161-75
pubmed: 23190170
West Indian Med J. 2014 Mar;63(2):134-7
pubmed: 25303246
J Low Genit Tract Dis. 2016 Jan;20(1):11-4
pubmed: 26704327
Obstet Gynecol. 2009 Apr;113(4):917-924
pubmed: 19305339
Am Fam Physician. 2002 Oct 1;66(7):1269-74
pubmed: 12387439
J Infect Dis. 2004 Jul 1;190(1):37-45
pubmed: 15195241
Eur Rev Med Pharmacol Sci. 2014;18(8):1277-85
pubmed: 24817305
J Cancer. 2017 Aug 25;8(15):2950-2958
pubmed: 28928886
Crit Rev Oncol Hematol. 2020 Mar;147:102866
pubmed: 32058913
Malawi Med J. 2021 Sep;33(3):186-195
pubmed: 35233276
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22
pubmed: 18628412
Int J Womens Health. 2015 Mar 20;7:305-13
pubmed: 25848321
Oncotarget. 2018 Jan 3;9(9):8725-8730
pubmed: 29492231
Int J Cancer. 2017 Sep 15;141(6):1161-1169
pubmed: 28577297
Papillomavirus Res. 2020 Dec;10:100202
pubmed: 32464334
PLoS One. 2019 Mar 11;14(3):e0213086
pubmed: 30856196
Ecancermedicalscience. 2015 Apr 29;9:531
pubmed: 25987900
AIDS. 2018 Mar 27;32(6):795-808
pubmed: 29369827
Int J Gynecol Cancer. 2011 Aug;21(6):967-74
pubmed: 21792008
J Natl Cancer Inst. 1997 Oct 15;89(20):1516-23
pubmed: 9337348
Br J Cancer. 2009 Jul 7;101(1):27-31
pubmed: 19513077
Syst Rev. 2020 Apr 22;9(1):88
pubmed: 32321580
Int J Gynecol Cancer. 2014 May;24(4):758-65
pubmed: 24651632
J Reprod Med. 1999 Sep;44(9):766-8
pubmed: 10509298
Obstet Gynecol Clin North Am. 2017 Sep;44(3):339-352
pubmed: 28778635
Clin Infect Dis. 2004 Mar 1;38(5):737-42
pubmed: 14986260